Israeli biotech Redhill announced positive top-line results from its confirmatory Phase 3 study using its TALICIA treatment for H. pylori Infection. Of 455 trial participants, the antibiotic-resistant infection was eradicated completely in 85% of cases compared to 58% using an alternative.
https://www.redhillbio.com/RedHill/Templates/showpage.asp?TMID=178&FID=1384&PID=0&IID=10196